Resistance to aminoglycoside antibiotics has commonly followed clinical use of these agents (4) . Resistance to gentamicin among the Enterobacteriaceae and Pseudomonas aeruginosa appears to be a problem of increasing importance (5, 12) . At the Wadsworth VA Hospital amikacin was shown to be the most effective aminoglycoside in vitro against gentamicin-resistant Enterobacteriaceae and P. aeruginosa (8, 12) . Likewise, it has been highly effective in treating infections caused by gentamicin-resistant, gram-negative bacilli (11) .
Netilmicin (Sch 20569) is a new semisynthetic aminoglycoside related to sisomicin, a dehydrogenated analogue of gentamicin Cia, but it contains an additional ethyl group on the central ring (15) . Rahal et al. have compared netilnicin in vitro with amikacin and gentamicin against gentamicin-susceptible and gentamicin-resistant gram-negative bacilli and have shown considerable activity (15) . Early clinical investigation with netilmicin indicates that the blood levels achieved are equal to or greater than those achieved with gentamicin, which it closely resembles pharmacologically (L. S. Young, personal communication, 1976 ). This study was designed to compare the in vitro effectiveness ofnetilmicin with other aminoglycosides currently licensed or under clinical investigation, i.e., amikacin (8, 9, 11, 12, 15, 19, 20) , sisomicin (8, 9, 20) , and tobramycin (8, 9, 13, 20 (6, 10) . Freezethaw extraction of the agar media was performed. The magnesium content ofthe liquid extracted from 677 678 MEYER, KRAUS, AND PASIECZNIK the media, which was repeatedly frozen and thawed, was from 0.71 to 1.54 mg/100 ml (mean, 1.23 mg/100 ml on three determinations) as measured by atomic absorption spectrophotometry; these results are similar to previous measurements (12) . The minimal inhibitory concentration (MIC) was recorded as the lowest concentration ofantibiotic showing only a haze, one colony, or no growth after overnight incubation (3). Reference strains of Staphylococcus aureus ATCC 25923 and Escherichia coli ATCC 25922 were included in parallel tests. All determinations were made in duplicate or triplicate, and the MICs were expressed as averages. Only organisms with a gentamicin MIC :16 ,ug/ml in agar dilution testing or . 8 ,ug/ml in broth dilution testing were included.
Two hundred and twenty-four isolates fulfilled these criteria.
Because of the known effect of cation concentration and especially magnesium (6, 10; K. P. Fu and H. C. Neu, Abstr. Annu. Meet. Am. Soc. Microbiol. 1976, A30, p. 6) on susceptibility testing of aminoglycosides with P. aeruginosa, as well as our initial results of higher MICs to netilmicin with P. aeruginosa than with Enterobacteriaceae, broth dilution testing was performed in parallel with netilmicin, amikacin, and gentamicin. MICs in broth were performed as outlined (3) with an inoculum of approximately 5 x 10) organisms/ml. Minimal bactericidal concentrations were performed by inoculating approximately 0.01 ml from tubes showing no turbidity onto antibiotic-free agar plates and recording the concentration of antibiotic at which five or fewer colonies grew after overnight incubation. This corresponds to 99.9% or greater killing. The magnesium content of the broth was 0.35 to 0.53 mg/100 ml (mean, 0.42 mg/100 ml on 11 determinations). RESULTS P. aeruginosa. Amikacin showed the greatest degree of in vitro activity in agar testing (Fig. 1) . Gentamicin and the two most active agents in agar testing, amikacin and netilmicin, were also utilized in broth dilution testing (Fig. 2) . A greater difference between agar and broth MICs was seen with netilmicin than with either amikacin or gentamicin (Fig. 2) . Netilmicin broth MICs ranged from 2 to 16 times lower than agar MICs, but a smaller range was seen with amikacin. Various P. aeruginosa isolates that required 32 to 128 /.g of netilmicin per ml for inhibition in broth were inhibited by relatively lower concentrations of amikacin (.16 jig/ml), but cross-resistance was noted in some strains. Conversely, no isolate of P. aeruginosa resistant to amikacin in broth (MIC .32 ,tg/ml) was inhibited by netilmicin at a concentration of <16 ,tg/ml, and almost all of these organisms were inhibited by netilmicin only at a concentration of 64 to 128 ,lg/ml. S. marcescens. Both netilmicin and amikacin were highly effective in vitro. Sisomicin and tobramycin were considerably less active (Fig.  3) . Klebsiella pneumoniae. As with S. marcescens, netilmicin and amikacin were the most active agents in vitro (Fig. 4) .
Providencia stuartii. Amikacin was the most active agent. Netilmicin and sisomicin showed less activity than amikacin but were similar to each other (Fig. 5) .
Enterobacter sp. Netilmicin and amikacin were both highly active in vitro. Sisomicin was less active; tobramycin results were generally parallel to gentamicin (Fig. 6) .
E. coli. Netilmicin was the most active agent in vitro. Amikacin was also highly effective, but sisomicin and tobramycin again were less active (Fig. 7) .
Indole-positive Proteus sp. Amikacin was the most effective in vitro agent (Fig. 8) Our results also differ from those of Rahal et al. (15) , who demonstrated similar activity with netilmicin and amikacin against P. aeruginosa in broth testing. Our results show amikacin to be the most active against gentamicin-resistant P. aeruginosa when the anticipated blood levels are considered. Our previous studies showed a mean 1-h peak blood level of 27.6 ,ug/ml with amikacin (11) . On comparison on a weight basis, however, our results with P. aeruginosa are similar to those of Rahal et al. (15) in showing that netilmicin is the most active agent until the higher concentrations, when amikacin appears so.
The high degree of in vitro activity of amikacin against gentamicin-resistant Enterobacteriaceae and P. aeruginosa agrees with our previous findings reported in a smaller number of different clinical isolates (8, 12) . Although gentamicin and tobramycin are active against some strains ofProvidencia (7), our experience agrees with that of Overturf et al., who found gentamicin-resistant strains that were susceptible to amikacin (14) .
The wider range of amikacin than netilmicin against gentamicin-resistant organisms may be due to either permeability factors or to resistance to inactivation by enzymes produced by Rfactors. Amikacin is inactivated o mycin acetyltransferase (2) , which is also known as ammloglycoside acetyltransferase (6'). Netilmicin is inactivated not only by aminoglycoside acetyltransferase (6') but also by aminoglycoside acetyltransferase (2') and by aminoglycoside acetyltransferase (3' )-II (Kenneth E. Price, personal communication, 1976). These observations may explain the patterns of | resistance noted in our isolates, although assays for specific enzymes have not been performed.
Netilmicin has a wide range of activity in vitro against gentamicin-resistant Enterobacteriaceae and P. aeruginosa. Amikacin, however, remains the currently available agent that has the widest range of activity against these gentamicin-resistant organisms. Clinical studies with netilmicin are merited; studies of efficacy and toxicity comparing it to amikacin and other aminoglycosides are needed to determine its exact role.
